Evidence map›Paper›PMID 40841737›Full record

ArticleScientific reports2025

Exploring the metabolic-immune score in advanced NSCLC treated with immunotherapy.

Beliz Bahar Karaoğlan, Ecenur Dursun, İrem Mesci, Mine Soylu Araz, Elif Berna Köksoy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Beliz Bahar KaraoğlanFaculty of Medicine, Department of Medical Oncology, Ankara University, Cebeci, Ankara, 06100, Türkiye, Turkey. bbaharulas@gmail.com.ORCID http://orcid.org/0000-0002-5021-7588
Ecenur DursunFaculty of Medicine, Department of Nuclear Medicine, Ankara University, Ankara, Türkiye, Turkey.ORCID http://orcid.org/0000-0002-0379-6484
İrem MesciFaculty of Medicine, Department of Nuclear Medicine, Ankara University, Ankara, Türkiye, Turkey.ORCID http://orcid.org/0000-0003-4382-2795
Mine Soylu ArazFaculty of Medicine, Department of Nuclear Medicine, Ankara University, Ankara, Türkiye, Turkey.ORCID http://orcid.org/0000-0001-6467-618X
Elif Berna KöksoyFaculty of Medicine, Department of Medical Oncology, Ankara University, Cebeci, Ankara, 06100, Türkiye, Turkey.ORCID http://orcid.org/0000-0002-6590-4444

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identifying reliable prognostic markers in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) is critical for clinical decision-making. This study introduces the Metabolic and Immune Score (MIS), a novel scoring system combining metabolic and inflammatory markers. A retrospective analysis was conducted on 56 patients with advanced NSCLC treated with ICIs between January 2018 and January 2024. Baseline metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated using

Indexed as

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsAdultAgedAged, 80 and overFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedPositron Emission Tomography Computed TomographyPrognosisRetrospective StudiesTumor BurdenFluorodeoxyglucose F18Immune Checkpoint InhibitorsImmunotherapyLung immune prognostic indexMetabolic tumor volumeNon-small cell lung cancerTotal lesion glycolysis

Identifiers

PMID40841737
PMCPMC12371022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.